These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 23668989)

  • 1. New azole antagonists with high affinity for the P2Y(1) receptor.
    Ruel R; L'Heureux A; Thibeault C; Daris JP; Martel A; Price LA; Wu Q; Hua J; Wexler RR; Rehfuss R; Lam PY
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3519-22. PubMed ID: 23668989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Aminothiazole based P2Y(1) antagonists as novel antiplatelet agents.
    Pi Z; Sutton J; Lloyd J; Hua J; Price L; Wu Q; Chang M; Zheng J; Rehfuss R; Huang CS; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4206-9. PubMed ID: 23743287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benzofuran-substituted urea derivatives as novel P2Y(1) receptor antagonists.
    Thalji RK; Aiyar N; Davenport EA; Erhardt JA; Kallal LA; Morrow DM; Senadhi S; Burns-Kurtis CL; Marino JP
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4104-7. PubMed ID: 20542694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agent.
    Jeon YT; Yang W; Qiao JX; Li L; Ruel R; Thibeault C; Hiebert S; Wang TC; Wang Y; Liu Y; Clark CG; Wong HS; Zhu J; Wu DR; Sun D; Chen BC; Mathur A; Chacko SA; Malley M; Chen XQ; Shen H; Huang CS; Schumacher WA; Bostwick JS; Stewart AB; Price LA; Hua J; Li D; Levesque PC; Seiffert DA; Rehfuss R; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2014 Mar; 24(5):1294-8. PubMed ID: 24513044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Amino-1,3,4-thiadiazoles in the 7-hydroxy-N-neopentyl spiropiperidine indolinyl series as potent P2Y1 receptor antagonists.
    Hu CH; Qiao JX; Han Y; Wang TC; Hua J; Price LA; Wu Q; Shen H; Huang CS; Rehfuss R; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2481-5. PubMed ID: 24767843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility.
    Wang TC; Qiao JX; Clark CG; Jua J; Price LA; Wu Q; Chang M; Zheng J; Huang CS; Everlof G; Schumacher WA; Wong PC; Seiffert DA; Stewart AB; Bostwick JS; Crain EJ; Watson CA; Rehfuss R; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3239-43. PubMed ID: 23602442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent P2Y1 urea antagonists bearing various cyclic amine scaffolds.
    Ruel R; L'Heureux A; Thibeault C; Lapointe P; Martel A; Qiao JX; Hua J; Price LA; Wu Q; Chang M; Zheng J; Huang CS; Wexler RR; Rehfuss R; Lam PY
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6825-8. PubMed ID: 24269480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist.
    Qiao JX; Wang TC; Ruel R; Thibeault C; L'Heureux A; Schumacher WA; Spronk SA; Hiebert S; Bouthillier G; Lloyd J; Pi Z; Schnur DM; Abell LM; Hua J; Price LA; Liu E; Wu Q; Steinbacher TE; Bostwick JS; Chang M; Zheng J; Gao Q; Ma B; McDonnell PA; Huang CS; Rehfuss R; Wexler RR; Lam PY
    J Med Chem; 2013 Nov; 56(22):9275-95. PubMed ID: 24164581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of 2-(phenoxyaryl)-3-urea derivatives as novel P2Y
    Peng J; Zhao L; Wang L; Chen H; Qiu Y; Wang J; Yang H; Liu J; Liu H
    Eur J Med Chem; 2018 Oct; 158():302-310. PubMed ID: 30223118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demystifying P2Y
    Ciancetta A; O'Connor RD; Paoletta S; Jacobson KA
    J Chem Inf Model; 2017 Dec; 57(12):3104-3123. PubMed ID: 29182323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y₁₂ receptor.
    Bach P; Boström J; Brickmann K; van Giezen JJ; Groneberg RD; Harvey DM; O'Sullivan M; Zetterberg F
    Eur J Med Chem; 2013 Jul; 65():360-75. PubMed ID: 23747805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists.
    Chao H; Turdi H; Herpin TF; Roberge JY; Liu Y; Schnur DM; Poss MA; Rehfuss R; Hua J; Wu Q; Price LA; Abell LM; Schumacher WA; Bostwick JS; Steinbacher TE; Stewart AB; Ogletree ML; Huang CS; Chang M; Cacace AM; Arcuri MJ; Celani D; Wexler RR; Lawrence RM
    J Med Chem; 2013 Feb; 56(4):1704-14. PubMed ID: 23368907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional interaction between purinergic receptors: effect of ligands for A2A and P2Y12 receptors on P2Y1 receptor function.
    Suzuki T; Obara Y; Moriya T; Nakata H; Nakahata N
    FEBS Lett; 2011 Dec; 585(24):3978-84. PubMed ID: 22079667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two disparate ligand-binding sites in the human P2Y1 receptor.
    Zhang D; Gao ZG; Zhang K; Kiselev E; Crane S; Wang J; Paoletta S; Yi C; Ma L; Zhang W; Han GW; Liu H; Cherezov V; Katritch V; Jiang H; Stevens RC; Jacobson KA; Zhao Q; Wu B
    Nature; 2015 Apr; 520(7547):317-21. PubMed ID: 25822790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of acylurea isosteres of 2-acylaminothiadiazole in the azaxanthene series of glucocorticoid receptor agonists.
    Gong H; Yang M; Xiao Z; Doweyko AM; Cunningham M; Wang J; Habte S; Holloway D; Burke C; Shuster D; Gao L; Carman J; Somerville JE; Nadler SG; Salter-Cid L; Barrish JC; Weinstein DS
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3268-73. PubMed ID: 24980053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-Benzothiazole-7-hydroxyindolinyl diaryl ureas are potent P2Y1 antagonists with favorable pharmacokinetics: low clearance and small volume of distribution.
    Qiao JX; Wang TC; Hiebert S; Hu CH; Schumacher WA; Spronk SA; Clark CG; Han Y; Hua J; Price LA; Shen H; Chacko SA; Everlof G; Bostwick JS; Steinbacher TE; Li YX; Huang CS; Seiffert DA; Rehfuss R; Wexler RR; Lam PY
    ChemMedChem; 2014 Oct; 9(10):2327-43. PubMed ID: 24989964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors.
    Jacobsen EJ; Mitchell MA; Hendges SK; Belonga KL; Skaletzky LL; Stelzer LS; Lindberg TJ; Fritzen EL; Schostarez HJ; O'Sullivan TJ; Maggiora LL; Stuchly CW; Laborde AL; Kubicek MF; Poorman RA; Beck JM; Miller HR; Petzold GL; Scott PS; Truesdell SE; Wallace TL; Wilks JW; Fisher C; Goodman LV; Kaytes PS
    J Med Chem; 1999 May; 42(9):1525-36. PubMed ID: 10229623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor.
    Bach P; Boström J; Brickmann K; van Giezen JJ; Hovland R; Petersson AU; Ray A; Zetterberg F
    Bioorg Med Chem Lett; 2011 May; 21(10):2877-81. PubMed ID: 21507636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
    Hao M; Li Y; Wang Y; Yan Y; Zhang S; Li G; Yang L
    J Chem Inf Model; 2011 Oct; 51(10):2560-72. PubMed ID: 21923153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3,4-Diamino-1,2,5-thiadiazole as potent and selective CXCR2 antagonists.
    Biju P; Taveras AG; Yu Y; Zheng J; Hipkin RW; Fossetta J; Fan X; Fine J; Lundell D
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1434-7. PubMed ID: 19200721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.